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Abstract
Background: In prostate cancer, genes encoding androgen-regulated, Y-chromosome-encoded, and tissue-specific antigens
may all be overexpressed. In the adult male host, however, most high affinity T cells targeting these potential tumor
rejection antigens will be removed during negative selection. In contrast, the female mature T-cell repertoire should contain
abundant precursors capable of recognizing these classes of prostate cancer antigens and mediating effective anti-tumor
immune responses.
Methodology/Principal Findings: We find that syngeneic TRAMP-C2 prostatic adenocarcinoma cells are spontaneously
rejected in female hosts. Adoptive transfer of naı ¨ve female lymphocytes to irradiated male hosts bearing pre-implanted
TRAMP-C2 tumor cells slows tumor growth and mediates tumor rejection in some animals. The success of this adoptive
transfer was dependent on the transfer of female CD4 T cells and independent of the presence of CD25-expressing
regulatory T cells in the transferred lymphocytes. We identify in female CD4 T cells stimulated with TRAMP-C2 a dominant
MHC II-restricted response to the Y-chromosome antigen DBY. Furthermore, CD8 T cell responses in female lymphocytes to
the immunodominant MHC I-restricted antigen SPAS-1 are markedly increased compared to male mice. Finally, we find no
exacerbation of graft-versus-host disease in either syngeneic or minor-antigen mismatched allogeneic lymphocyte adoptive
transfer models by using female into male versus male into male cells.
Conclusions/Significance: This study shows that adoptively transferred female lymphocytes, particularly CD4 T cells, can
control the outgrowth of pre-implanted prostatic adenocarcinoma cells. This approach does not significantly worsen graft-
versus-host responses suggesting it may be viable in the clinic. Further, enhancing the available immune repertoire with
female-derived T cells may provide an excellent pool of prostate cancer reactive T cells for further augmentation by
combination with either vaccination or immune regulatory blockade strategies.
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Introduction
Despite improvements in detection and treatment, prostate
cancer (CaP) remains the second leading cause of cancer death
in men in the United States and the second most common
cancer in men worldwide. When localized, CaP is often curable
through first line therapies such as prostatectomy. Few curative
therapies exist, however, for recurrent or metastatic CaP.
Recently, sipuleucel-T, a vaccine designed to elicit an immune
response against prostatic acid phosphatase, was shown to
improve median survival of patients with metastatic castration-
resistant CaP [1]. Blockade of the immune regulatory molecule
CTLA-4 has also shown clinical promise for prostate cancer
[2,3]. Development of immunotherapeutic interventions which
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e e starget multiple aspects of the immune system in CaP may offer
greater clinical benefit and more durable responses. Develop-
ment of immunotherapeutic interventions which target multiple
antigens in CaP may offer greater clinical benefit and more
durable responses.
Prostate cancers likely express a constellation of potential tumor
antigens including mutated self-proteins [4], overexpressed
androgen-responsive and androgen-regulated proteins [5,6], and
differentially expressed tissue-specific and male Y-linked proteins
[7]. T cells developing in males which recognize any of these
androgen-related or Y-chromosome antigens with high affinity are
likely deleted during negative selection in the thymus. Low affinity
T cells which escape central deletion are in turn usually anergized
through peripheral tolerance mechanisms upon subsequent
antigen encounter. In contrast, the mature female T-cell repertoire
should contain an ample frequency of T-cell precursors capable of
recognizing all of the above classes of prostate cancer antigens.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is one means of altering a patient’s immune repertoire and
overcoming immune regulatory mechanisms. Rigorous chemo-
therapeutic and/or radiation conditioning programs ablate the
host’s hematopoietic system, which is then reconstituted with bone
marrow or mobilized stem cells from a suitable donor. These
donor cells expand in the patient giving rise to a new immune
system which can recognize malignant cells in the patient as
foreign in a process termed the graft-versus-tumor (GVT) effect
[8,9]. GVT can lead to complete and lasting remissions in patients
with cancers that cannot otherwise be cured with chemotherapy or
radiation. For this reason, allo-HSCT is widely utilized in the
treatment of a variety of hematologic malignancies.
In addition to mediating desirable GVT effects, donor immune
cells can also attack normal host tissues resulting in graft-versus-
host disease (GVHD). GVHD in both the acute and chronic forms
is a major source of morbidity and mortality in recipients of allo-
HSCT. Choice of allogeneic donor is known to potentially impact
on the risk of developing GVHD; male recipients of female grafts,
for example, have an elevated risk of both acute and chronic
GVHD, particularly those with female donors who have
undergone multiple pregnancies [10–12].
Adoptive transfer of autologous ex vivo expanded tumor-
infiltrating or engineered tumor-specific T cells has shown curative
potential for both metastatic melanoma and chronic lymphoid
leukemia [13]. These approaches, however, require considerable
expertise and often weeks of culturing to expand T cells. By
adoptively transferring syngeneic naı ¨ve female lymphocytes into
male mice pre-implanted with prostate tumors, we sought to test
the potential of the female T-cell repertoire to recognize and
attack CaP. To improve the expansion of adoptively transferred
cells as well as reduce the risk for GVHD and potentially augment
GVT effects, we treated recipient mice with nonmyeloablative
doses of radiation, given prior reports that a mixed chimeric state
can promote GVT responses while minimizing GVHD [14,15].
Results
Female Mice Immunologically Reject TRAMP-C2 Prostatic
Adenocarcinoma Cells
In the transgenic adenocarcinoma of mouse prostate (TRAMP)
model, tumors that develop are initially androgen-dependent but
later become androgen-independent, recapitulating the normal
progression of prostate cancer in humans [16]. For our studies, we
utilized the TRAMP-C2 cell line derived from these mice. These
transplantable CaP cells form tumors when implanted into
C57BL6 mice, are partially androgen-sensitive in vitro, and express
a mutated version of the SPAS-1 protein which is the target of the
dominant CD8 T-cell response [17].
We challenged female mice, young male mice, and mature male
mice with TRAMP-C2 cells and measured the growth of tumors
over time (Figure 1A). Tumors grew robustly in adult male mice,
but grew more slowly in young male mice perhaps due to either
lower androgen levels or lack of immune tolerance to androgen-
regulated genes. In female mice, however, TRAMP-C2 tumors
grew initially and then spontaneously regressed. The ability of
these tumors to grow initially suggested that their disappearance
was due to immunological rejection rather than a dependence on
high levels of androgens for sustained growth. To confirm this
hypothesis, we repeated the tumor challenge in bone marrow
chimeras in which we transplanted female and male T-cell
depleted bone marrow into female hosts. TRAMP-C2 tumors
were completely rejected in female-into-female chimeras, whereas
in male-into-female chimeras TRAMP-C2 tumors grew progres-
sively (Figure 1B). Interestingly, female mice transplanted with a
mixture of female and male bone marrow were also unable to
mediate tumor rejection. This experiment demonstrates that these
prostate cancer cells do not require male androgen levels for
sustained growth in vivo, and that their rejection in female mice is
mediated by the hematolymphoid system. Furthermore, the
presence of male hematopoietic cells appears to have a dominant
suppressive effect on the ability of female hematopoietic cells to
reject TRAMP-C2 tumors, perhaps due to thymic negative
selection mediated by expression of male antigens in bone
marrow-derived thymic dendritic cells.
The results from the male-into-female chimera mice also
implied that the impaired growth of TRAMP-C2 cells in pre-
pubescent 5-week old mice was likely due to incomplete immune
tolerance to adult-male prostate cancer rather than a lack of
sufficient androgen levels. To more directly evaluate for the
potential impact of androgen levels as well as other age-induced
differences, we challenged adult male mice of the same age (8
weeks) that were surgically castrated either early (at 4 weeks of age
prior to onset of puberty), or late (one week prior to tumor
challenge). We found that adult male mice that had not undergone
puberty due to early castration displayed significantly delayed
growth of TRAMP-C2 tumors (Figure 1C). While TRAMP-C2
cells are routinely cultured in the presence of dihydrotestosterone
[16], our results demonstrate that TRAMP-C2 can develop
progressive tumors in vivo in the absence of testes-derived
androgens, possibly due to the presence of androgens originating
from other endocrine organs such as androstenedione produced by
the adrenal glands. Indeed, the TRAMP mouse model, from
which TRAMP-C2 originates, is known to produce prostate
adenocarcinomas that can progress despite castration [18]. Our
data further suggest that while some potential for immune
recognition of mature prostate antigens exists in males at an early
age, tolerance against these prostate antigens is developed
following puberty and leads to accelerated tumor growth.
Adoptive Transfer of Female Lymphocytes into Male
Mice Pre-implanted with TRAMP-C2 Cells Slows Tumor
Growth and Occasionally Mediates Tumor Rejection
Having observed that rejection of CaP cells in female mice was
mediated by the hematopoietic system, we asked if transferring a
female hematopoietic system into male mice would render them
resistant to TRAMP-C2 tumor challenge. We generated bone
marrow chimeras in which male hosts were transplanted with
female T-cell depleted bone marrow. Despite having a hemato-
poietic system of female origin, TRAMP-C2 tumors grew readily
in these chimeric mice (Figure 2A). This suggests that female-
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develop in a male host. Tolerance of these cells may be both due to
thymic ‘‘education’’ mediated by male radioresistant thymic
epithelial cells, and by peripheral tolerance mechanisms engaged
when these female T cells encounter the prostate and other male
tissues.
To bypass central tolerance mechanisms, we next evaluated the
potential of mature female lymphocytes to transfer anti-CaP
immunity. These cells have undergone thymic selection in the
female donor prior to transfer, and, therefore, should contain T
cells capable of recognizing Y chromosome, androgen-regulated,
prostate tissue-specific, and mutational antigens. We administered
to male mice a nonmyeloablative dose of radiation to induce
lymphopenia and create space for our transferred cells. Later the
same day, mice were challenged with TRAMP-C2 tumor cells.
One day later, either male or female splenocytes were infused into
these tumor-challenged mice. We found that while infusion of
male splenocytes had no effect on tumor growth, female
splenocytes mediated a significant delay in tumor growth and
improved tumor-free survival, in some cases leading to complete
tumor rejection (Figure 2B).
By transferring total splenocytes, we are transferring
CD4+CD25+FoxP3+ regulatory T cells (Treg) in addition to
the effector T cells responsible for the GVT effects. It is possible,
particularly using male donor mice, that these Treg cells may
impede the efficacy of the transferred effectors. To ensure that
our observations were not being compromised by the presence of
Treg cells, we used magnetic beads to deplete Tregs from the
adoptively transferred lymphocytes leaving less than 1% FoxP3+
cells remaining in the graft (data not shown). Depletion of Treg
cells did not improve the efficacy of either female or male
adoptively transferred lymphocytes (Figure 2C). This suggests
that the primary determinant of GVT efficacy is the antigen
specificity of the transferred effector cells, and that donor Treg
cells do not have a significant impact on GVT.
To clarify the relative contributions of CD4 and CD8 T cells in
mediating control of tumor growth by female splenocytes, we
performed a mix-and-match experiment using male and female
donors that were depleted in vivo with antibodies against either
CD4 or CD8. Interestingly, we found that transfer of female CD4
T cells mediated similar tumor control when transferred with CD8
T cells of either male or female origin, while male CD4 T cells
were unable to mediate tumor control even when infused
simultaneously with female CD8 T cells (Figure 2D). Altogether,
these results suggest that naı ¨ve CD4 T cells from female mice are
essential for controlling growth of TRAMP-C2 tumors in male
mice, while female CD8 T cells are not required.
Female DBY-specific CD4 T Cells Potentiate the CD8 T-
cell Response Against TRAMP-C2 Tumor Antigens
ToconfirmthatCD4Tcellsplayapivotalroleindirectingfemale
immune responses against prostate cancer, we performed experi-
mentstoidentifyTcellresponsesagainstspecificepitopesofantigens
expressed by TRAMP-C2. Previously, we identified SPAS-1, an
antigen on chromosome 2 expressed by TRAMP-C2 with an
immunodominant class I epitope arising from a spontaneous point
mutation [17]. By RT-PCR, we also identified expression of known
class I-restricted Y chromosome antigens including SMCY, UTY,
and EIAFIAY, as well as expression of class II-restricted Y
chromosome antigen DBY (data not shown). It has been reported
Y antigens are often selectively overexpressed in human CaP cell
lines and tumors [7]. Similarly, we found that the genes for smcy,
uty, and dby appeared to be selectively overexpressed in the
TRAMP-C2 cell line and in spontaneously arising prostate tumor
from TRAMP mice compared to normal B6 prostate (Figure S1).
To compare immune responses to TRAMP-C2 antigens arising
in male and female mice, we utilized a cellular vaccine composed
of irradiated GM-CSF-overexpressing TRAMP-C2 cells
(TRAMP-GM-CSF) which we had previously generated and
characterized [19]. We assayed vaccinated male and female mice
for CD4 and CD8 T cells responses against known and predicted
Figure 1. Female mice reject TRAMP-C2 prostate cancers while male mice develop tolerance following puberty. A) TRAMP-C2 tumor
cells grow progressively in adult male mice, with a slower kinetic but complete penetrance in pre-pubescent male mice, and grow briefly but then are
rejected in adult female mice. n=5 mice/group, one of 2 experiments with similar results. B) Adult female mice were transplanted with female, male,
or a 1:1 mixture of female and male T-cell depleted bone marrow and 10 weeks after transplantation challenged with TRAMP-C2 tumors. n=5 mice/
group, results of a single experiment. C) Preventing onset of puberty in male mice can mediate delayed growth of TRAMP-C2 tumors. Adult male
mice surgically castrated before onset of puberty (4 weeks) show delayed growth of TRAMP-C2, while castration 1 week prior to tumor challenge (7
weeks) had no effect on tumor growth. n=10 mice/group, tumor growth curve and area under curve normalized to median value for group 3 from
each experiment. Combined results of 2 experiments.
doi:10.1371/journal.pone.0035222.g001
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stimulation with peptide-pulsed dendritic cells, we evaluated T-
cell production of IFN-c. We found that vaccination of female
mice with TRAMP-GM-CSF results in strong CD4 T cell
responses against DBY, while male mice do not develop
measurable responses against DBY, though female and male
CD4 T cells had similar responses to stimulation with anti-
CD3e/anti-CD28 beads, or with phorbol myristate acetate
(PMA) and ionomycin (Figure 3A). Likely this is due to the lack
of central tolerance against DBY in female versus male mice and
the high expression of DBY by TRAMP-C2 cells. We found that
male mice do mount CD8 T cell responses against the mutated
antigen SPAS-1 following TRAMP-C2 cell vaccination. Female
CD8 T cells, however, exhibit stronger responses to SPAS-1 than
males (Figure 3A), an unexpected finding given that expression of
SPAS-1 is neither gender-restricted nor hormone-regulated. The
responses to SPAS-1 was dominant over responses to other
antigens, including Y-chromosome antigens SMCY, UTY, and
EIAFIY, as well as responses to the six transmembrane epithelial
antigen of the prostate (STEAP), which had been reported due to
be immunogenic in male mice and selectively overexpressed in
prostate tumors [20]. Altogether, these results suggest that female
DBY-specific CD4 T cells are able to potentiate CD8 T cell
responses against an immunodominant tumor antigen arising
from a spontaneous mutation.
To determine if a similar phenomenon of DBY-specific CD4
T cell ‘‘help’’ was occurring in the setting of adoptive cellular
therapy, we transferred either male or female splenocytes into
male hosts and then vaccinated with a DNA plasmid expressing
mutated SPAS-1. We found that male mice that received female
splenocytes spontaneously developed CD4 T-cell responses
against DBY, evidenced by intracellular production of IFN-c.
Remarkably, males that received female splenocytes developed
strong CD8 T-cell responses to SPAS-1 vaccination, while males
Figure 2. Adoptive transfer of female lymphocytes into male mice challenged with TRAMP-C2 controls tumor growth. A) Adult male
mice were myeloablated via irradiation and transplanted with female T-cell depleted bone marrow followed by challenge with TRAMP-C2 tumors 10
weeks after transplantation. n=5 mice/group, results of a single experiment. B) Adult male mice were sublethally irradiated with 6 Gy and challenged
intradermally with 1610
6 TRAMP-C2. The following day, mice received a donor lymphocyte infusion (DLI) of 3610
7 splenocytes i.v. n=10 mice/group,
one of 3 experiments with similar results. C) Adoptively-transferred CD25+ regulatory T cells do not mediate increased tumor growth seen following
male DLI. Mice were irradiated and tumor-challenged as in B, and received splenocytes that were CD25-depleted using magnetic beads where
indicated. n=10 mice/group, results of a single experiment. D) Female CD4 T cells mediate delayed growth of TRAMP-C2 tumors. Mice were
irradiated and tumor-challenged as in B, and then received 1.5610
7 splenocytes that were in vivo CD4-depleted, mixed with 1.5610
7 splenocytes that
were CD8-depleted, of either male or female origin. n=10 mice/group, one of 2 experiments with similar results.
doi:10.1371/journal.pone.0035222.g002
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SPAS-1 vaccination (Figure 3B). Results of these adoptive
transfer experiments indicate that possible mechanisms for
improved control of tumor growth in male recipients of female
lymphocytes include both CD4 and CD8 T-cell recognition of
antigens expressed by TRAMP-C2.
Adoptive Transfer of Female Lymphocytes into
Lymphopenic Male Hosts does not Result in Significant
GVHD
In our female-into-male immune transplant models, we have
actively monitored for clinical signs of GVHD, which can include
weight loss as well as changes in activity, posture, skin and fur. We
have seen no evidence for GVHD in these experiments. In the
bone marrow transplant setting, however, selecting a female donor
can lead to an increased risk of GVHD [10–12]. In order to
further investigate the safety of adoptive female cellular therapy for
patients with prostate cancer, we evaluated histologically for
subclinical evidence of GVHD in two models, B6 into B6
(syngeneic) and LP into B6 (MHC-matched, minor antigen-
mismatched allogeneic), looking at GVHD target organs including
liver, small intestine, and large intestine. We found that in the
syngeneic setting, at two different time points (days 21 and 42 after
transfer) female lymphocytes did not produce significantly more
GVHD than male lymphocytes (Figure 4). In the more clinically
relevant setting of an MHC-matched, minor-antigen mismatched
model, we found a similar degree of GVHD using female and
male donors at both early and late time points. Overall, GVHD
pathological scores observed in these sublethal irradiation
lymphocyte transfer models were mild in comparison to the
MHC-mismatched bone marrow transplant with allogeneic T cell
setting (Figure 4), confirming our observations that GVHD is mild
Figure 3. Female lymphocytes strongly recognize the CD4 antigen DBY and the CD8 antigen SPAS-1. A) Immunization of females with
TRAMP-GMCSF cells produces augmented CD4 responses against DBY and CD8 responses against SPAS-1. Male and female B6 mice were injected
intradermally with 1610
6 irradiated TRAMP-GMCSF at days 29, 26, and 23 prior to sacrifice. CD4+ and CD8+ splenocytes were purified with
magnetic beads and restimulated with CD11c+ female splenic DCs pulsed with the indicated peptide, or alternatively were stimulated with anti-
CD3e/anti-CD28 beads, or with phorbol myristate acetate (PMA) and ionomycin. Supernatant concentrations of IFN-c and other cytokines were
assayed by BD cytometric bead array. Results of a single experiment. B) DNA vaccination with SPAS-1 produces immune responses in male mice
adoptively transferred with female lymphocytes. Male B6 mice were given 6 Gy irradiation followed by male or female adoptive lymphocyte transfer.
Mice were vaccinated by gene gun with SPAS-1-expressing DNA plasmids on days 1, 7, and 13 following adoptive transfer. On day 19, splenocytes
were incubated with or without the SPAS-1 and DBY peptides, and production of IFN-c by CD4 and CD8 T cells was evaluated by intracellular flow
cytometry. Results of a single experiment.
doi:10.1371/journal.pone.0035222.g003
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appear to increase the incidence or severity of GVHD.
Discussion
Here we report that adoptively transferred naı ¨ve female
lymphocytes slow the growth of and, in some cases, reject pre-
implanted TRAMP-C2 prostatic adenocarcinoma cells in suble-
thally irradiated male mice. A similar finding has also been
recently reported by Yi et. al, who also used TRAMP-C2 cells
[21]. They identified T cells as mediators of anti-prostate cancer
immune responses in female mice and found that adoptive transfer
of vaccinated female lymphocytes can lead to control of growth of
TRAMP-C2 tumors in male hosts. Our study supports their initial
findings and expands on them considerably by identifying
mechanisms by which the female immune system mounts superior
responses to prostate cancer. We demonstrate that female CD4 T
cells are essential mediators of this effect, particularly those specific
for the immunodominant epitope from the male antigen DBY.
While Yi et. al found that female mice immunized with TRAMP-
C2 developed some T-cell responses against normal prostate tissue
as well as the prostate antigen STEAP, our data demonstrate that
responses to STEAP are relatively minor in comparison with
responses to the spontaneously arising immunodominant tumor
antigen mutated SPAS-1, which was not assayed for in the
previous study. Our results indicate that CD4 T cell responses
against DBY, which are unique to female immune repertoires, can
markedly augment CD8 T cell responses against a spontaneously
arising mutant tumor antigen such as SPAS-1. CD4 T cell
responses to DBY appear to be particularly robust in the setting of
I-Ab MHC II restriction; T cells derived from mice bearing a
transgenic T-cell receptor specific for the same DBY epitope have
been previously shown capable of mounting responses against
TRAMP-C2 tumors in RAG knockout mice [22]. We found that
female lymphocytes in a male host were also able to mount
superior responses to vaccination against SPAS-1, in the setting of
concurrently developing spontaneous responses to DBY.
It is possible that CD4 T cells specific for DBY can supply help
for CD8 T cells that mediate GVHD as well as GVT. However,
by utilizing a model with sublethal irradiation followed by
lymphocyte transfer without co-transfer of hematopoietic stem
cells, we were able to markedly minimize graft-versus-host disease
effects. Male mice treated with large doses of female lymphocytes
had no clinical evidence for graft-versus-host disease and only very
mild pathological evidence. At the same time, however, this
approach may have allowed the establishment of tolerance to male
and prostate antigens recognized by transferred female-derived T
cells, potentially limiting the efficacy of this strategy and resulting
in less mice fully rejecting their tumors.
Many of the recent advances in tumor immunotherapy have
focused on either vaccination strategies or blockade of immune
regulatory mechanisms. Two recent immune strategies that
obtained FDA approval include vaccination against sipuleucel-T
for metastatic CaP [1], and antibody-mediated blockade of the T-
cell negative co-stimulatory receptor CTLA-4 for the treatment of
metastatic melanoma [23]. The goal of vaccination strategies are
to generate new anti-tumor T cell responses, while immune
regulatory blockade strategies seek to release endogenous anti-
tumor immune responses that are generated spontaneously but
restrained and ineffective [24]. While both approaches show
promise, clinical data show that most patients eventually still
succumb to progression of their cancer. Combinations of immune
approaches may be the most promising. In this study, we identify a
third approach, namely enhancement of the immune repertoire by
adoptively transferring sex-mismatched lymphocytes with im-
proved ability to recognize tumor antigens. Repertoire enhance-
ment has the potential to dynamically synergize with both tumor
vaccination and immune regulatory blockade strategies.
For metastatic castration-resistant prostate cancer, a disease
which continues to have a poor prognosis, we show that female
lymphocytes, particularly CD4 T cells, adoptively transferred into
prostate-cancer challenged male mice can mediate substantial
anti-tumor effects. In terms of safety, this approach appears
clinically viable as we observed no substantial GVHD in either
syngeneic or MHC-matched, minor mismatched allogeneic female
to male lymphocyte transfers. The data presented here supports
further evaluation of this approach to prostate cancer immuno-
Figure 4. Adoptively transferred female lymphocytes do not produce increased graft-versus-host disease. Male B6 mice were given 6
Gy irradiation followed by an i.v. infusion of 3610
7 splenocytes, either male or female, from syngeneic B6 or allogeneic LP donors. For comparison,
female B6 mice were lethally irradiated (11 Gy) and transplanted with 5610
6 T-cell depleted bone marrow cells and 2610
6 purified splenic T cells
from MHC-mismatched B10.BR mice (H2k into H2b). Mice were evaluated on the day indicated for histological evidence of GVHD in the liver, small
intestine, and large intestine. Results of a single experiment.
doi:10.1371/journal.pone.0035222.g004
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immunotherapeutic approaches.
Materials and Methods
Mice
All mouse procedures were performed in accordance with
institutional protocol guidelines at Memorial Sloan-Kettering
Cancr Center (MSKCC). Mice were maintained according to
NIH Animal Care guidelines, under protocols approved by the
MSKCC Institutional Animal Care Committee describing exper-
iments specific to this study. C57BL/6 and LP mice were obtained
from the Jackson Laboratory.
Antibodies
CD4 (GK1.5) and CD8 (2.43) depleting antibodies were
purchased from Bio-Xcell. Flow cytometry was performed using
antibodies recognizing CD45 (30-F11), CD4 (RM4–5), CD8a (53–
6.7), IFN-c (XMG1.2) purchased from BD Biosciences.
Peptides
All peptides used were purchased from Biosynthesis, Inc. and
used at a final concentration of 10 mm. CD8 peptides included
SPAS-1 (244–252), SMCY (738–746), UTY (246–254), EIAFIY
(63–71) and STEAP (262–270, 327–335). CD4 peptides included
DBY (608–622) and as a control, Pep25, the dominant MHC class
II-presented epitope of M. tuberculosis Ag85B [25].
Cell Lines
TRAMP-C2 tumor cells were provided by Dr. Norman
Greenberg [26] and cultured as previously described [16].
TRAMP-GM-CSF cells have also been previously described [19].
BMT
All transplantation protocols were reviewed and approved by
the Memorial Sloan-Kettering Cancer Center IACUC. Trans-
plantation protocols have been previously described [27].
Surgical Castration
Mice were anesthetized and a small scrotal incision made to
reveal the testes. These were sutured and removed along with
surrounding fatty tissue. The wound was closed using surgical
staples.
TRAMP-C2 Gender Challenge
5-week old male, 8 week old male, and 8 week old female mice
were challenged with 5610
5 TRAMP-C2 cells intradermally on
the right flank and monitored for tumor growth.
Lymphocyte Adoptive Transfer
Recipient mice were rendered lymphopenic with non-myeloa-
blative (6 Gy) whole body irradiation. Following irradiation, mice
were rested for 4–8 hours and then implanted with 1610
6
TRAMP-C2 cells intradermally. On the following day, splenocytes
were purified from 8–10 week old donor male or female C57BL/6
mice and 3610
7 per mouse were transferred via tail vein injection
to the recipient animals. Treg cells were removed from transferred
lymphocyte populations where indicated using the Miltenyi Biotec
CD4+CD25+ isolation kit according to the manufacturer’s
instructions. For CD4 and CD8 mix and match experiments,
mice were either depleted of CD4 T cells with the GK1.5 antibody
(for CD8 transfer) or depleted of CD8 T cells with the 2.43
antibody (for CD4 transfer). Depletions consisted of 2 injections of
500ug of the depleting antibody at days 26 and 22 prior to
transfer. Mix and match adoptive transfers were performed as
above except that 1.5610
7 splenocytes from various CD4 depleted
mice were transferred in combination with 1.5610
7 splenocytes
from the indicated CD8 depleted mice.
SPAS-1 DNA Vaccination
On days 1, 7, and 13 following irradiation and lymphocyte
transfer, mice were vaccinated by gene gun with SPAS-1-
expressing DNA plasmids as previously reported [28]. Briefly,
plasmid DNA was purified, coated onto 1-mm diameter gold
particles (Alfa Aesar, Ward Hill, MA), and allowed to settle on
bullets of Teflon tubing. Gold particles containing 1 mg DNA were
delivered to each abdominal quadrant by the use of a helium-
driven gene gun (Accell; PowderMed, Oxford, United Kingdom),
for a total of 4 mg DNA per mouse. Mice were vaccinated on days
1, 7, and 13 following DLI. On day 19, splenocytes were
incubated with or without the SPAS-1 and DBY peptides in the
presence of GolgiPlug (BD Biosciences), and production of IFN-c
by CD8 and CD4 T cells was evaluated by intracellular flow
cytometry.
TRAMP-specific T-cell Responses
Male and female C57BL/6 mice were vaccinated with 1610
6
TRAMP-C2 cells expressing GM-CSF intradermally at days 29,
26, and 23 prior to sacrifice. Draining lymph nodes were
removed and CD4 and CD8 T cells were purified using positive
selection beads from Miltenyi Biotech. Female CD11c+ dendritic
cells were purified from spleens of naı ¨ve mice using Miltenyi
positive selection beads and pulsed with 10 mm of the indicated
peptide for 6–8 hours. Purified T cells were incubated with peptide
pulsed DCs and production of cytokines including IFN-c was
measured after 48 hours of incubation using the BD TH1/TH2/
TH17 cytometric bead array as previously described [29]. Positive
controls included purified T cells from vaccinated mice poly-
clonally activated using either Mouse T-activator aCD3/CD28
beads (Life Technologies) or using 50 ng/ml phorbol myristate
acetate (PMA) and 1 mg/ml ionomycin (Sigma).
Evaluation of GVHD
Mice were monitored daily for survival and weekly for GVHD
clinical scores [30]. Small intestine, large intestine, and liver
samples were evaluated histologically for evidence of GVHD and
scored as previously described [31].
Supporting Information
Figure S1 Selective overexpression of some Y-antigens
by TRAMP tumors. RNA was purified from the indicated
tumor cell line or primary tissue using TRI-ZOL (Invitrogen). The
RNA was reverse-transcribed into cDNA using the Superscript II
RT Kit (Invitrogen). PCR was then performed using Taq
Polymerase Mastermix from Qiagen and gene-specific primers
as indicated. b-Actin was amplified in parallel to standardize for
cDNA content and quality between samples.
(TIF)
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